Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1668355

registered interest
date	08/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Department of Health and Social Care: Civil Servants
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the 3,310 total headcount figure for permanent civil servants excluding agency workers working for his Department as of 31 March 2023, as detailed in Cabinet Office statistics entitled Permanent and temporary civil servants by sex, age band and department: 2023, published on 31 October 2023, what that figure was on 31 March (a) 2011, (b) 2016 and (c) 2020.
tabling member constituency	Islington South and Finsbury
tabling member printed	Emily Thornberry
uin	739
answer	answer is ministerial correction date of answer 22/11/2023 answer text <p>On 2 October 2023, the Chancellor announced an immediate cap on civil servant headcount across Whitehall to stop any further expansion, increase efficiencies and boost productivity.</p><p>The Civil Service grew to manage the impact of the COVID-19 pandemic and the illegal war in Ukraine, but it is right that we reduce the size of the Civil Service over time as we drive up productivity and deliver efficiencies.</p><p>The following table shows the total headcount figure for permanent civil servants working for the Department, excluding agencies:</p><table><tbody><tr><td><p>31 March 2011</p></td><td><p>31 March 2016</p></td><td><p>31 March 2020</p></td></tr><tr><td><p>Total Departmental headcount</p></td><td><p>2615</p></td><td><p>1952</p></td><td><p>1741</p></td></tr></tbody></table> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/11/2023 16:16:12 answering member 4044 label Biography information for Andrew Stephenson
tabling member	1536 label Biography information for Emily Thornberry

1668389

registered interest
date	08/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Neurology: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he has taken to help ensure that integrated care boards are (a) ready and (b) supported to commission neurology services identified as suitable for delegation.
tabling member constituency	Waveney
tabling member printed	Peter Aldous
uin	765
answer	answer is ministerial correction date of answer 16/11/2023 answer text <p>To support assurance of integrated care board (ICB) readiness for taking on greater responsibility for in-scope specialised services, a pre-delegation assessment framework was developed, which set out the criteria that ICBs should meet prior to assuming responsibility for the functions, and builds on the primary care pharmaceutical, general ophthalmic and dental commissioning functions framework. ICBs, with the support of their regional team, undertook a self-assessment against the pre-delegation assessment framework for specialised commissioning. Final decisions will be taken by the NHS England board later this year.</p><p>The NHS England Neurology Transformation Programme has developed, in partnership with stakeholders, a new whole pathway neurology model to support ICBs to deliver the right service, at the right time for all neurology patients including providing care closer to home. A toolkit is being developed to support ICBs to understand and implement this new model. It will provide them with resources and information they will need to drive transformation in their neurology services, as they take on delegated responsibility for commissioning specialised neurology services from April 2024 onwards.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 16/11/2023 13:43:12 answering member 4117 label Biography information for Andrea Leadsom
tabling member	4069 label Biography information for Peter Aldous

1668391

registered interest
date	08/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress he has made on (a) establishing and (b) defining the priorities of the Highly Specialised Services Programme Board.
tabling member constituency	Waveney
tabling member printed	Peter Aldous
uin	767
answer	answer is ministerial correction date of answer 17/11/2023 answer text <p>We will not define the priorities of the Highly Specialised Services Programme Board. NHS England established the Highly Specialised Services Oversight Group (HSSOG), previously referred to as the Highly Specialised Services Programme Board, in April 2023 to ensure that there is a continued clear focus on highly specialised services and rare diseases.</p><p>HSSOG is the operational group responsible for discharging NHS England’s duties, powers and responsibilities in respect of the 80 highly specialised services. HSSOG’s membership is across the United Kingdom and includes representation from integrated care boards.</p><p>HSSOG takes its strategic clinical advice and clinical leadership from the Rare Diseases Advisory Group and has a role in implementing the England Rare Diseases Action Plan.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 17/11/2023 09:49:59 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4069 label Biography information for Peter Aldous

1668411

registered interest
date	08/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Ophthalmic Services: Special Educational Needs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what proportion of children in receipt of the NHS Special Schools Eye Care Service have a history of hospital-based eye care.
tabling member constituency	Mitcham and Morden
tabling member printed	Siobhain McDonagh
uin	662
answer	answer is ministerial correction date of answer 16/11/2023 answer text <p>From April 2021 to September 2023, there have been 15,858 sight tests completed under the NHS Special Schools Eye Care Service. Of these, 10,785 have no history of hospital-based eye care attached to them, 1,672 are listed as being active in hospital-based eye care and 3,401 have been discharged from hospital.</p><p>From the 15,858 sight tests, 6,784 were issued with glasses. NHS England does not hold information on other sight problems in this cohort of patients.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom grouped question UIN 663 question first answered 16/11/2023 13:29:03 answering member 4117 label Biography information for Andrea Leadsom
tabling member	193 label Biography information for Dame Siobhain McDonagh

1668413

registered interest
date	08/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Ophthalmic Services: Special Educational Needs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will visit an NHS special schools eye care service.
tabling member constituency	Mitcham and Morden
tabling member printed	Siobhain McDonagh
uin	664
answer	answer is ministerial correction date of answer 16/11/2023 answer text <p>Ministers regularly consider visits to health and care settings across the country. Any plans to visit specific locations will be notified to hon. Members in advance.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 16/11/2023 13:41:12 answering member 4117 label Biography information for Andrea Leadsom
tabling member	193 label Biography information for Dame Siobhain McDonagh

1668422

registered interest
date	08/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Abiraterone
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the potential impact of the level of availability of abiraterone on the NHS on the health of prostate cancer patients.
tabling member constituency	Haltemprice and Howden
tabling member printed	Mr David Davis
uin	672
answer	answer is ministerial correction date of answer 17/11/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body that provides evidence-based guidance for the National Health Service on whether new medicines represent a clinically- and cost-effective use of resources. The NHS is legally required to fund medicines recommended by NICE, usually within three months of final guidance.</p><p>NICE has published guidance recommending abiraterone for the treatment of hormone-relapsed metastatic prostate cancer before chemotherapy is indicated and for the castration-resistant variant of that cancer previously treated with a docetaxel-containing regimen. NHS England funds abiraterone for these indications of prostate cancer in line with NICE’s recommendations, making it routinely available for the treatment of eligible patients.</p><p>Abiraterone is not licensed for the treatment of non-metastatic prostate cancer and has therefore not been appraised by NICE for such use. NHS England is considering a clinical policy proposal for abiraterone as a treatment option for patients newly diagnosed with high risk, non-metastatic, hormone-sensitive prostate cancer, or in whom prostate cancer has relapsed after at least 12 months without treatment. This specific policy proposal is due to be discussed later in November 2023 and if supported by a clinical panel it will progress to stakeholder testing by January 2024.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 673 674 question first answered 17/11/2023 12:37:56 answering member 4044 label Biography information for Andrew Stephenson
tabling member	373 label Biography information for Sir David Davis

1668423

registered interest
date	08/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Abiraterone
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of bringing forward the planned review of abiraterone as a treatment for prostate cancer on the NHS.
tabling member constituency	Haltemprice and Howden
tabling member printed	Mr David Davis
uin	673
answer	answer is ministerial correction date of answer 17/11/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body that provides evidence-based guidance for the National Health Service on whether new medicines represent a clinically- and cost-effective use of resources. The NHS is legally required to fund medicines recommended by NICE, usually within three months of final guidance.</p><p>NICE has published guidance recommending abiraterone for the treatment of hormone-relapsed metastatic prostate cancer before chemotherapy is indicated and for the castration-resistant variant of that cancer previously treated with a docetaxel-containing regimen. NHS England funds abiraterone for these indications of prostate cancer in line with NICE’s recommendations, making it routinely available for the treatment of eligible patients.</p><p>Abiraterone is not licensed for the treatment of non-metastatic prostate cancer and has therefore not been appraised by NICE for such use. NHS England is considering a clinical policy proposal for abiraterone as a treatment option for patients newly diagnosed with high risk, non-metastatic, hormone-sensitive prostate cancer, or in whom prostate cancer has relapsed after at least 12 months without treatment. This specific policy proposal is due to be discussed later in November 2023 and if supported by a clinical panel it will progress to stakeholder testing by January 2024.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 672 674 question first answered 17/11/2023 12:37:56 answering member 4044 label Biography information for Andrew Stephenson
tabling member	373 label Biography information for Sir David Davis

1668424

registered interest
date	08/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Abiraterone
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the cost effectiveness of the use of abiraterone as a treatment for prostate cancer by the NHS.
tabling member constituency	Haltemprice and Howden
tabling member printed	Mr David Davis
uin	674
answer	answer is ministerial correction date of answer 17/11/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body that provides evidence-based guidance for the National Health Service on whether new medicines represent a clinically- and cost-effective use of resources. The NHS is legally required to fund medicines recommended by NICE, usually within three months of final guidance.</p><p>NICE has published guidance recommending abiraterone for the treatment of hormone-relapsed metastatic prostate cancer before chemotherapy is indicated and for the castration-resistant variant of that cancer previously treated with a docetaxel-containing regimen. NHS England funds abiraterone for these indications of prostate cancer in line with NICE’s recommendations, making it routinely available for the treatment of eligible patients.</p><p>Abiraterone is not licensed for the treatment of non-metastatic prostate cancer and has therefore not been appraised by NICE for such use. NHS England is considering a clinical policy proposal for abiraterone as a treatment option for patients newly diagnosed with high risk, non-metastatic, hormone-sensitive prostate cancer, or in whom prostate cancer has relapsed after at least 12 months without treatment. This specific policy proposal is due to be discussed later in November 2023 and if supported by a clinical panel it will progress to stakeholder testing by January 2024.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 672 673 question first answered 17/11/2023 12:37:56 answering member 4044 label Biography information for Andrew Stephenson
tabling member	373 label Biography information for Sir David Davis

1668450

registered interest
date	08/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Inflammatory Bowel Disease: Diagnosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to increase the early diagnosis of (a) Crohn’s disease and (b) ulcerative colitis.
tabling member constituency	Loughborough
tabling member printed	Jane Hunt
uin	949
answer	answer is ministerial correction date of answer 16/11/2023 answer text <p>To support healthcare professionals in the early diagnosis and management of inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, the National Institute for Health and Care Excellence (NICE) has produced a range of guidance, including guidance specifically on the use of faecal calprotectin tests as a way of diagnosing inflammatory bowel disease (IBD). NICE’s IBD quality standard outlines that referral to a specialist assessment for suspected IBD should be within four weeks.</p><p>NICE guidelines represent best practice and health professionals, including general practitioners, and service commissioners are expected to take them fully into account. Guidelines published by NICE are not mandatory and do not replace the judgement of clinicians in determining the most appropriate treatment for individual patients.</p><p>In addition, NHS England’s Getting it Right First Time (GIRFT) specialty report on gastroenterology, published in September 2021, sets out actions and recommendations for the National Health Service to improve patient care and ensure consistency of care across the country.</p><p>It is the responsibility of integrated care boards to make available appropriate provision to meet the health and care needs of their local population, including the diagnosis and management of IBD.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/11/2023 17:10:29 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4839 label Biography information for Jane Hunt

1668451

registered interest
date	08/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Inflammatory Bowel Disease: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to improve care provided to patients with (a) Crohn's disease and (b) ulcerative colitis.
tabling member constituency	Loughborough
tabling member printed	Jane Hunt
uin	950
answer	answer is ministerial correction date of answer 17/11/2023 answer text <p>To support healthcare professionals in the early diagnosis and management of inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, the National Institute for Health and Care Excellence (NICE) has produced a range of guidance, including guidance specifically on the use of faecal calprotectin tests as a way of diagnosing inflammatory bowel disease (IBD). NICE’s IBD quality standard outlines that referral to a specialist assessment for suspected IBD should be within four weeks.</p><p>NICE guidelines represent best practice and health professionals, including general practitioners, and service commissioners are expected to take them fully into account. Guidelines published by NICE are not mandatory and do not replace the judgement of clinicians in determining the most appropriate treatment for individual patients.</p><p>In addition, NHS England’s Getting it Right First Time (GIRFT) specialty report on gastroenterology, published in September 2021, sets out actions and recommendations for the National Health Service to improve patient care and ensure consistency of care across the country.</p><p>It is the responsibility of integrated care boards to make available appropriate provision to meet the health and care needs of their local population, including the diagnosis and management of IBD.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 17/11/2023 15:40:06 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4839 label Biography information for Jane Hunt